These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38899670)

  • 1. Enhancing the Management of Benign Prostatic Hyperplasia: The Role of Electronic Health Record Patient Portal Distribution of the International Prostate Symptom Score.
    Zhu D; Mali K; Bandari J; Jain RK; Quarrier SO
    Urol Pract; 2024 Jul; 11(4):709-715. PubMed ID: 38899670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Viktrup L; Hayes RP; Wang P; Shen W
    BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
    O'Leary MP; Wei JT; Roehrborn CG; Miner M;
    BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between intravesical prostatic protrusion and international prostate symptom score among Nigerian men with benign prostatic hyperplasia.
    Eze BU; Mbaeri TU; Oranusi KC; Abiahu JA; Nwofor AM; Orakwe JC; Mbonu OO
    Niger J Clin Pract; 2019 Apr; 22(4):454-459. PubMed ID: 30975947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRI evaluation of benign prostatic hyperplasia: Correlation with international prostate symptom score.
    Guneyli S; Ward E; Peng Y; Nehal Yousuf A; Trilisky I; Westin C; Antic T; Oto A
    J Magn Reson Imaging; 2017 Mar; 45(3):917-925. PubMed ID: 27487205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study].
    Fourcade RO; Picot MC; Gaudin AF; Texier N; Slama A
    Presse Med; 2007 May; 36(5 Pt 1):755-63. PubMed ID: 17329070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
    Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
    J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of glucose metabolism, insulin resistance and inflammatory factors with symptom score of patients with benign prostatic hyperplasia.
    Zhou B; Wang P; Xu WJ; Li YM; Tong DL; Jiang J; Sun ZY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(16):5077-5081. PubMed ID: 30178825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microwave thermotherapy for benign prostatic hyperplasia.
    Hoffman RM; Monga M; Elliott SP; Macdonald R; Langsjoen J; Tacklind J; Wilt TJ
    Cochrane Database Syst Rev; 2012 Sep; (9):CD004135. PubMed ID: 22972068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multifaceted Assessment of Benign Prostatic Hyperplasia Practice and AUA Guideline Adherence.
    Welliver C; MacLachlan LS; Riggs S; Kukreja JB; Miles-Thomas J
    Urol Pract; 2024 Nov; 11(6):950-955. PubMed ID: 39196671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
    Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
    BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of transurethral resection of prostate in clinical benign prostatic hyperplasia.
    Bozdar HR; Memon SR; Paryani JP
    J Ayub Med Coll Abbottabad; 2010; 22(4):194-6. PubMed ID: 22455296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
    Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
    Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
    Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
    Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
    Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
    World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
    Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
    Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
    Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of electroacupuncture and its cotreatment with electronic moxibustion in the treatment of patients with moderate benign prostatic hyperplasia using alpha blocker: Study protocol for an assessor-blinded, randomized controlled clinical trial.
    Kim HB; Kim YI; Jeon JH; Kim E; Kim JY; Kwon O; Choi YE; Yang C; Han CH
    Medicine (Baltimore); 2020 Apr; 99(15):e19678. PubMed ID: 32282720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.